Stay up to date with our latest news and events.
Solubility is an important consideration at any stage of recombinant protein production.
Proteos is excited to announce the expansion of our services to include intact mass analysis using LC ESI-MS.
Thank you to our valued customers for your business and support in 2022. We wish you a joyous holiday season and look forward to working with you in 2023.
Proteos would like to wish you a very Happy Thanksgiving!
Fusion proteins are often used to increase the expression and solubility of the target protein but may negatively affect the functionality of the target protein in biochemical or structural studies.
Proteos stands ready to help you complete your 2022 discovery research goals before the end of the year.
The design and placement of a fusion protein partner relative to the protein of interest must be critically considered and empirically tested since it can significantly affect protein expression and function.
Our transient mammalian cell expression system can be used to produce functional fusion proteins with extended in vivo half-life for use in pre-clinical proof of concept (POC) studies, through selection of an appropriate fusion partner.
There are many variables to consider when producing novel recombinant proteins. These variables include selection of an expression system, construct design, and scale. In the upcoming months, we will focus on the use of fusion proteins for recombinant protein expression in mammalian cell systems including purpose, selection, placement, and removal.
There are many variables to consider when producing novel recombinant proteins. Here we will focus on the importance of performing small-scale expression optimization.
